Form 10-Q · Quarterly report
Mastercard 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0001141391
- Accession no.
- 0001141391-26-000124
Summary
Mastercard repurchased 22.9 million Class A shares for $11.893 billion in the nine months ended September 30, 2026, leaving $5.568 billion under its share repurchase authorizations, and reported that its disclosure controls and procedures were effective. CEO Michael Miebach, CFO Hai Ling, and Corporate Controller Christopher Mullett signed the quarterly report.
Key points
- Mastercard's board approved a $14.0 billion Class A share repurchase program in December 2025, effective March 2026 after a $12.0 billion 2024 program was completed.
- Mastercard repurchased $648 million of shares from October 1 through October 26, 2026.
- A hypothetical 10% adverse change in functional currencies would result in about $340 million fair value net loss on Mastercard's foreign exchange derivative contracts outstanding at September 30, 2026, before offsetting hedged activity.
- Mastercard's CEO and CFO concluded disclosure controls and procedures were effective as of September 30, 2026, and no material change in internal control over financial reporting occurred in the third quarter of 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Repurchased shares of our common stock are considered treasury stock. In December 2025 and 2024, our Board of Directors approved programs authorizing us to repurchase shares of our Class A common stock up to $14.0 billion and $12.0 billion, respectively. The program approved in 2025 became effective in March 2026, after the completion of the program approved in 2024. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.